Laxai Pharma EBITDA 2010-2010 | LAXAF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Laxai Pharma ebitda from 2010 to 2010. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Laxai Pharma ebitda from 2010 to 2010. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$148.1B
CVS Health (CVS)	$75.9B
Elevance Health (ELV)	$65B
Cencora (COR)	$56.2B
DiDi Global (DIDIY)	$25.7B
Labcorp Holdings (LH)	$21.9B
Natera (NTRA)	$18.5B
BioMerieux (BMXMF)	$17.1B
EUROFINS SCIENT (ERFSF)	$15.2B
ICON (ICLR)	$15B
CochLear (CHEOY)	$13.6B
Solventum (SOLV)	$12.7B
Medpace Holdings (MEDP)	$12.6B
Revvity (RVTY)	$11.1B
Viatris (VTRS)	$10.8B
Avantor (AVTR)	$9.5B
Sonic Healthcare (SKHHY)	$9.1B
Charles River Laboratories (CRL)	$8.8B
HealthEquity (HQY)	$8.3B
Caris Life Sciences,�Inc (CAI)	$7B
Bausch + Lomb (BLCO)	$5.2B
Amplifon S.p.A (AMFPF)	$5.1B
BrightSpring Health Services (BTSG)	$3.5B
Sotera Health (SHC)	$3.4B
Surgery Partners (SGRY)	$2.9B
Organon (OGN)	$2.6B
GeneDx Holdings (WGS)	$2.6B
Concentras Parent (CON)	$2.6B
Alignment Healthcare (ALHC)	$2.3B
Progyny (PGNY)	$2B